Skip to main
IMUX
IMUX logo

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc. is positioned for a positive outlook due to impressive early-stage results from its drug candidates, particularly IMU-856, which demonstrated significant increases in GLP-1 production in patients, potentially reflecting broader metabolic benefits. The potential for IMU-856 to address unmet needs beyond its initial target of gut epithelial restoration, along with the readiness for Phase 2 development, suggests a robust opportunity for strategic partnerships or financing. Additionally, preclinical studies indicating weight management benefits associated with IMU-856 further support its viability as a promising therapeutic option in treating chronic inflammatory and autoimmune diseases.

Bears say

Immunic Inc. faces significant risks to its investment thesis, primarily due to the potential for its developmental candidates to fall short of peak commercial revenue estimates linked to market size, penetration rates, and pricing challenges. Additionally, the company's reliance on securing adequate capital resources to fund ongoing operations poses a further financial risk. Lastly, the uncertainty surrounding the continued development and commercialization of its pipeline products may adversely impact investor confidence and financial stability.

Immunic Inc (IMUX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Buy based on their latest research and market trends.

According to 13 analysts, Immunic Inc (IMUX) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.